Multiple myeloma (MM) is a plasma cell malignancy defined by complex genetics and
extensive patient heterogeneity. Despite a growing arsenal of approved therapies, MM …

High throughput drug screening is an established approach to investigate tumor biology and
identify therapeutic leads. Traditional platforms use two-dimensional cultures which do not …

The international precision oncology program INFORM enrolls relapsed/refractory pediatric
cancer patients for comprehensive molecular analysis. We report a two-year pilot study …

Many efforts are underway to develop novel therapies against the aggressive high-grade
serous ovarian cancers (HGSOCs), while our understanding of treatment options for low …

Precision medicine is starting to incorporate functional assays to evaluate anticancer agents
on patient-isolated tissues or cells to select for the most effective. Among these new …

Simple Summary Children with acute myeloid leukemia (AML) experience unacceptably
poor survival outcomes and are at high risk of relapse. Current treatment options are limited …

Allogeneic hematopoietic stem cell transplantation (HSCT) provides patients with severe
hematologic disease a well-established potential for curation. Incorporation of germline …

Acute myeloid leukemia (AML) remains a disease of gloomy prognosis despite intense
efforts to understand its molecular foundations and to find efficient treatments. In search of …

Simple Summary Glioblastoma, the most common and malignant brain tumor, is driven by a
population of stem and progenitor cells. We have recently demonstrated that identification of …

Background Functional profiling of freshly isolated glioblastoma (GBM) cells is being
evaluated as a next-generation method for precision oncology. While promising, its success …